Ways2Capital Reviews : AstraZeneca Receives Marketing Permission For Durvalumab (ImfinziTM) In India

AstraZeneca Pharma India Limited (AZPIL) announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses.

The stock is currently trading at Rs1,388 up by Rs35.5 or 2.62% from its previous closing of Rs1,352.50 on the BSE.

The scrip opened at Rs1,381 and has touched a high and low of Rs1,420 and Rs1,381 respectively.

Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.

Durvalumab is a patented product of AstraZeneca global.

Gagan Singh, Managing Director, AstraZeneca Pharma India Limited said, “The import and market permission for Durvalumab for unresectable stage III Non-Small Cell Lung Cancer (NSCLC) and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options. In India, approximately one third of patients with NSCLC are present with Stage III disease and we are excited to bring the first immunotherapy into this setting for patients.”

AstraZeneca’s Durvalumab is a part of a new class of immunotherapy drugs known as ‘checkpoint inhibitors’. Some forms of bladder and lung cancer use the PD-L1 protein to evade the immune system. Durvalumab, is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai